Safe Prescribing Through Reporting Act of 2025
- Bill Number
- H.R. 3595
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-05-23: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2025-09-17T08:06:46Z
AI-Generated Summary
Purpose
The "Safe Prescribing Through Reporting Act of 2025" (H.R. 3595) aims to improve the monitoring of medications used to treat substance use disorders (SUDs), such as opioids or other controlled substances, by allowing limited sharing of related patient records with state programs that track prescriptions. This supports safer prescribing practices and helps address issues like overprescribing or misuse amid the ongoing public health challenges with substance abuse.
Key Provisions
- Amends Section 543(b)(2) of the Public Health Service Act (42 U.S.C. 290dd-2(b)(2)) by adding a new subparagraph (E).
- Permits the disclosure of SUD medication records (specifically those related to prescribing or dispensing such medications) to a state's prescription drug monitoring program (PDMP), which is a state-run database that tracks controlled substance prescriptions to prevent abuse.
- Disclosure is allowed only if:
- The record pertains to SUD medications.
- State law requires such sharing.
Significant Changes to Existing Law
- Expands the exceptions to confidentiality rules for SUD patient records under federal law, which previously protected these records more strictly to encourage treatment-seeking without fear of disclosure.
- Introduces a targeted allowance for sharing with state PDMPs, bridging federal privacy protections with state-level monitoring needs, without altering broader confidentiality requirements.
Potential Impacts
- On government agencies: State health departments and PDMPs gain access to more comprehensive data, potentially improving coordination with federal programs like those under the Substance Abuse and Mental Health Services Administration (SAMHSA). Federal agencies may see reduced administrative burdens in complying with state requests.
- On citizens: Patients receiving SUD treatment could benefit from better oversight to prevent diversion or overdose risks, but it raises concerns about privacy; disclosures are limited, so most records remain protected. Healthcare providers might prescribe more cautiously, potentially reducing misuse of medications.
- On international relations: No direct impact, as the bill focuses on domestic U.S. health policy and state-federal interactions.
Main Stakeholders Affected
- Patients with substance use disorders: Their treatment records may be shared in limited cases, affecting privacy but aiming to enhance care safety.
- Healthcare providers (doctors, pharmacists): Required to report SUD medications to PDMPs where state law mandates, influencing prescribing habits.
- State governments and PDMP operators: Empowered with federal data to strengthen monitoring and public health responses.
- Federal health agencies (e.g., SAMHSA, HHS): Involved in overseeing compliance and ensuring disclosures align with national standards.
Notable Legal, Constitutional, or Political Implications
- Legal: Reinforces the balance between federal confidentiality protections (rooted in laws like 42 CFR Part 2, which safeguards SUD records more stringently than general health privacy rules under HIPAA) and state authority over prescription monitoring. It could lead to increased litigation if disclosures are perceived as overreaching privacy rights, but the state-law trigger limits federal overreach.
- Constitutional: Touches on privacy expectations under the Fourth Amendment (unreasonable searches) and due process, but the bill's narrow scope and voluntary treatment context likely avoid major challenges; it promotes public health without mandating disclosures.
- Political: Aligns with bipartisan efforts to combat the opioid epidemic, potentially influencing future legislation on drug policy. It may spark debates on privacy versus public safety, especially in states with varying PDMP laws, but avoids partisan divides by focusing on technical amendments.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (7)
Rep. Haridopolos, Mike [R-FL-8], Rep. Maloy, Celeste [R-UT-2], Rep. Hamadeh, Abraham J. [R-AZ-8], Rep. Onder, Robert F. [R-MO-3], Rep. Miller-Meeks, Mariannette [R-IA-1], Rep. Harris, Andy [R-MD-1], Rep. Johnson, Julie [D-TX-32]
Recent Actions
- 2025-05-23: Referred to the House Committee on Energy and Commerce.
- 2025-05-23: Introduced in House
- 2025-05-23: Introduced in House
Bill Versions
- Safe Prescribing Through Reporting Act of 2025 — issued 2025-05-23 — PDF (2 pages)